A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes

A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes

Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes

Inclusion Criteria:

• Age >18 years old；
• Enlargement of at least one intrathoracic LN (short diameter > 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET / CT (standardized uptake value > 2.5)；
• CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA;
• Patients who have good compliance and sign informed consent.

Exclusion Criteria:

• Patients with known hypersensitivity to ultrasound contrast components;
• Patients with severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg);
• Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting;
• Patients with uncontrolled essential hypertension and adults with respiratory distress syndrome;
• Pregnant or lactating women；
• Patients with contraindications to bronchoscopy；
• Patients with other conditions that, in the opinion of the investigator, make the patient unsuitable for the study.